Share Twitter LinkedIn Facebook Email Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still in develop for the convenience of multiple myeloma (MM) patients.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read